User menu

Statistical and radiobiological analysis of the so-called thyroid stunning.

Bibliographic reference Walrand, Stephan ; Hesse, Michel ; Jamar, François. Statistical and radiobiological analysis of the so-called thyroid stunning.. In: E J N M M I Research, Vol. 5, no.1, p. 67 [1-6] (2015)
Permanent URL
  1. Jeevanram R.K., Shah D.H., Sharma S.M., Ganatra R.D., Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients, 10.1016/0883-2897(86)90108-x
  2. MCDOUGALL I. R., 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer : , 10.1097/00006231-199706000-00002
  3. Bajén MT, Mañé S, Muñoz A, Garcia JR. Effect of diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J Nucl Med. 2000;41:2038–42.
  4. Dam Hung Q., Kim Sung M., Lin Henry C., Intenzo Charles M., 131I Therapeutic Efficacy Is Not Influenced by Stunning after Diagnostic Whole-Body Scanning, 10.1148/radiol.2322030528
  5. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine, and the controversy of “thyroid stunning”. Nucl Med Commun. 2004;25:883–9.
  6. Hilditch Thomas E., Dempsey Mary F., Bolster Alison A., McMenemin Rhona M., Reed Nicholas S., Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I, 10.1007/s00259-002-0785-6
  7. Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619–25.
  8. Woolfenden JM. Thyroid stunning revisited. J Nucl Med. 2006;47:1403–5.
  9. Sisson JC, Avram AM, Lawson SA, Gauger PG, Doherty GM. The so-called stunning of thyroid tissues. J Nucl Med. 2006;47:1406–12.
  10. Gerard SK, Park HM. Stunning effect. J Nucl Med. 2007;48:328–9. author reply: 329-330.
  11. Hilditch T. E., Bolster A. A., Dempsey M. F., Reed N. S., Re: The So-Called Stunning of Thyroid Tissue, 10.2967/jnumed.106.037788
  12. Filesi M, Colandrea M, Montesano T, D'Apollo R, Ronga G. Thyroid stunning in clinical practice: is it a real problem? Minerva Endocrinol. 2008;34:29–36.
  13. Kalinyak Judy E., McDougall I. Ross, Whole-body scanning with radionuclides of iodine, and the controversy of ???thyroid stunning??? : , 10.1097/00006231-200409000-00004
  14. McDougall I. Ross, Iagaru Andrei, Thyroid Stunning: Fact or Fiction?, 10.1053/j.semnuclmed.2010.10.004
  15. Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells. J Nucl Med. 2002;43:828–34.
  16. Lundh C, Nordén M, Nilsson M, Forssell-Aronsson E. Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med. 2007;48:481–6.
  17. Norden M. M., Larsson F., Tedelind S., Carlsson T., Lundh C., Forssell-Aronsson E., Nilsson M., Down-regulation of the Sodium/Iodide Symporter Explains 131I-Induced Thyroid Stunning, 10.1158/0008-5472.can-07-0823
  18. . Accessed 13 November 2015.
  19. Lundh C., Lindencrona U., Postgard P., Carlsson T., Nilsson M., Forssell-Aronsson E., Radiation-Induced Thyroid Stunning: Differential Effects of 123I, 131I, 99mTc, and 211At on Iodide Transport and NIS mRNA Expression in Cultured Thyroid Cells, 10.2967/jnumed.108.061150
  20. Cheng Weiwei, Ma Chao, Fu Hongliang, Li Jianing, Chen Suyun, Wu Shuqi, Wang Hui, Low- or High-Dose Radioiodine Remnant Ablation for Differentiated Thyroid Carcinoma: A Meta-Analysis, 10.1210/jc.2012-3682
  21. Castagna M. G., Cevenini G., Theodoropoulou A., Maino F., Memmo S., Claudia C., Belardini V., Brianzoni E., Pacini F., Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients, 10.1530/eje-12-0954
  22. Han Ji Min, Kim Won Gu, Kim Tae Yong, Jeon Min Ji, Ryu Jin-Sook, Song Dong Eun, Hong Suck Joon, Shong Young Kee, Kim Won Bae, Effects of Low-Dose and High-Dose Postoperative Radioiodine Therapy on the Clinical Outcome in Patients with Small Differentiated Thyroid Cancer Having Microscopic Extrathyroidal Extension, 10.1089/thy.2013.0362
  23. Du Peizhun, Jiao Xuelong, Zhou Yanbing, Li Yu, Kang Shan, Zhang Dongfeng, Zhang Jizhun, Lv Liang, Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials, 10.1007/s12020-014-0333-8
  24. Abdulrezzak U, Tutus A, Isik I, Kurt Y, Kula M. The quantitative comparison of low dose and standard dose radio iodine therapy effectiveness in patients with low risk differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2015 Jan 20. [Epub ahead of print]
  25. Brahme A., Argren A. K., Optimal Dose Distribution for Eradication of Heterogeneous Tumors, 10.3109/02841868709104364
  26. Gaussen Anthony, Legal Jean-Denis, Beron-Gaillard Nadine, Laplanche Agnés, Travagli Jean-Paul, Caillou Bernard, Parmentier Claude, Radiosensitivity of human normal and tumoral thyroid cells using fluorescence in situ hybridization and clonogenic survival assay, 10.1016/s0360-3016(99)00059-0
  27. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–72.
  28. Nahum AE. Converting dose distributions into tumour control probability. IAEA 1996 Accessed 13 November 2015.
  29. McParland Brian J, Nuclear Medicine Radiation Dosimetry, ISBN:9781848821255, 10.1007/978-1-84882-126-2
  30. The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP. 2007; 37:1-332
  31. Barendsen G. W., Walter H. M. D., Effects of Different Ionizing Radiations on Human Cells in Tissue Culture: IV. Modification of Radiation Damage, 10.2307/3571569
  32. Johansson L., Leide-Svegborn S., Mattsson S., Nosslin B., Biokinetics of Iodide in Man: Refinement of Current ICRP Dosimetry Models, 10.1089/108497803322285206
  33. Gibson WG, Peng TC, Croker BP. Age-associated C-cell hyperplasia in the human thyroid. Am J Pathol. 1982;106:388–93.
  34. Medvedec Mario, Seeking a radiobiological explanation for thyroid stunning, 10.1007/s002590000466
  35. Modoni S, Martino G, Valle G, Perrone E, Frusciante V. How is thyroid remnant ablation affected by former 131-1 diagnostic doses and/or elapsed time? Eur J Nucl Med Mol Imaging. 2000;27:1152.
  36. Kappler M, Rot S, Taubert H, Greither T, Bartel F, Dellas K, Hänsgen G, Trott K-R, Bache M, The effects of knockdown of wild-type survivin, survivin-2B or survivin-Δ3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions, 10.1038/sj.cgt.7701090
  37. Amin Amr, Amin Mahasen, Badwey Ahmed, Stunning phenomenon after a radioactive iodine-131 diagnostic whole-body scan : Is it really a point of clinical consideration?, 10.1097/mnm.0b013e328362ad63
  38. El-Saban K, Al-Sakhri H, Al-Zahrani A. Effect of stunning of diagnostic 131-iodine doses on ablative doses for differentiated thyroid cancer patient’s outcome. J Sol Tum. 2013;3:11–9.
  39. Yap Beng Khiong, Murby Brian, No Adverse Affect in Clinical Outcome Using Low Preablation Diagnostic131I Activity in Differentiated Thyroid Cancer: Refuting Thyroid-Stunning Effect, 10.1210/jc.2014-1405
  40. Etchebehere Elba C. S. C., Santos Allan O., Matos Patrícia S., Assumpção Lígia V. M., Lima Maria Cecília V. L., Lima Mariana C. L., Ward Laura S., Is thyroid stunning clinically relevant? A retrospective analysis of 208 patients, 10.1590/0004-2730000002989
  41. Hu Ya-Hui, Wang Pei-Wen, Wang Shan-Tair, Lee Chiang-Hsuan, Chen Hue-Yong, Chou Fong-Fu, Huang Yu-Erh, Huang Hsu-Hua, Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation : , 10.1097/01.mnm.0000126626.17166.ed
  42. Verburg FA, Verkooijen RB, Stokkel MP, van Isselt JW. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin. 2009;48:138–42.